Axenfeld-Rieger syndrome is an autosomal-dominant disorder caused by mutations in the PITX2 homeodomain protein. We have studied the mechanism underlying the dominant negative K88E mutation, which occurs at position 50 of the homeodomain. By using yeast two-hybrid and in vitro pulldown assays, we have documented that PITX2a can form homodimers in the absence of DNA. Moreover, the K88E mutant had even stronger dimerization ability, primarily due to interactions involving the C-terminal region. Dimerization allowed cooperative binding of wild-type (WT) PITX2a to DNA containing tandem bicoid sites in a head-to-tail orientation (Hill coefficient, 1.73). In contrast, the WT-K88E heterodimer bound the tandem sites with greatly reduced cooperativity and decreased transactivation activity. To further explore the role of position 50 in PITX2a dimerization, we introduced a charge-conservative mutation of lysine to arginine (K88R). The K88R protein had greatly reduced binding to a TAATCC element and did not specifically bind any other TAATNN motif. Like K88E, K88R formed relatively stronger dimers with WT. As predicted by our model, the K88R protein acted in a dominant negative manner to suppress WT PITX2a activity. These results suggest that the position 50 residue in the PITX2 homeodomain plays an important role in both DNA binding and dimerization activities.The PITX2 gene was cloned based on its linkage in Axenfeld-Rieger syndrome (ARS) (30). ARS is an autosomal-dominant human disorder characterized by ocular anterior chamber anomalies causing glaucoma in more than 50% of affected individuals as well as dental hypoplasia, mild craniofacial dysmorphism, and umbilical stump abnormalities. Other features associated with this syndrome include abnormal cardiac, limb, and pituitary development (28,30). Three isoforms of PITX2 (designated a, b, and c) that differ only in their amino termini have been identified (9, 15). PITX2a and the related PITX1 protein have been shown to interact with Pit-1, a transcription factor that regulates pituitary cell differentiation, including the expression of the thyroid-stimulating hormone, growth hormone, and prolactin genes (4, 16, 31). We have used the prolactin promoter as a model target for studying PITX2a activities. Transient transfection assays with the prolactin promoter, which contains both Pit-1 and PITX2a binding sites, have shown a strong synergistic effect of PITX2a and Pit-1 on transactivation (4). Consistent with these data, knockout mice lacking Pitx2 show arrested pituitary gland development (10).PITX2a is a 33-kDa homeodomain protein that is a functional member of the bicoid homeodomain subfamily, as defined by a lysine at residue 50 of the homeodomain (4). It has been demonstrated that this residue in the bicoid protein interacts with base pairs 5 and 6 of the hexanucleotide consensus 5Ј-TAATCC-3Ј (12, 32). PITX2a has been shown to specifically bind to this consensus sequence and transactivate corresponding reporter genes (4). We have previously reported an ARS mutation th...